Paul W Spearman

Summary

Affiliation: Emory University
Country: USA

Publications

  1. ncbi Tetherin does not significantly restrict dendritic cell-mediated HIV-1 transmission and its expression is upregulated by newly synthesized HIV-1 Nef
    Christopher M Coleman
    Center for Retrovirus Research, Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA
    Retrovirology 8:26. 2011
  2. ncbi Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial
    Paul Spearman
    Department of Pediatrics, Pediatric Infectious Diseases, Emory University School of Medicine, 2015 Uppergate Drive, Atlanta, GA 30322, United States
    Vaccine 27:243-9. 2009
  3. ncbi A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers
    Paul Spearman
    Department of Pediatrics, Emory University and Children s Healthcare of Atlanta, Georgia 30322, USA
    J Infect Dis 203:1165-73. 2011
  4. ncbi The tetherin/BST-2 coiled-coil ectodomain mediates plasma membrane microdomain localization and restriction of particle release
    Jason Hammonds
    Emory University Department of Pediatrics, Atlanta, Georgia, USA
    J Virol 86:2259-72. 2012
  5. ncbi Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein
    Peter F Wright
    Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Infect Dis 189:1221-31. 2004
  6. ncbi Emerging studies of human HIV-specific antibody repertoires
    Mark D Hicar
    Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Vaccine 28:B18-23. 2010
  7. ncbi Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV
    Mark D Hicar
    Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232 2905, USA
    J Acquir Immune Defic Syndr 54:223-35. 2010

Research Grants

  1. Viral and Cellullar Determinants of HIV-1 Assembly
    Paul W Spearman; Fiscal Year: 2010
  2. Viral and Cellular Determinants of HIV-1 Assembly
    Paul Spearman; Fiscal Year: 2005
  3. Role of VPU in Retroviral Particle Assembly
    Paul Spearman; Fiscal Year: 2007
  4. Viral and Cellular Determinants of HIV-1 Assembly
    Paul Spearman; Fiscal Year: 2007
  5. Pseudovirion Formation by Live Vector HIV Vaccines
    Paul Spearman; Fiscal Year: 2007
  6. Novel Assays for Inhibitors of HIV Assembly
    Paul Spearman; Fiscal Year: 2007
  7. Defining Neutralization Breadth in HIV+ Human Serum
    Paul W Spearman; Fiscal Year: 2010
  8. Development of Enhanced HIV-1 Pseudovirion Vaccines
    Paul Spearman; Fiscal Year: 2006
  9. Novel FRET-based Assays for HIV Assembly Inhibitors
    Paul Spearman; Fiscal Year: 2004
  10. Role of VPU in Retroviral Particle Assembly
    Paul W Spearman; Fiscal Year: 2011

Collaborators

Detail Information

Publications7

  1. ncbi Tetherin does not significantly restrict dendritic cell-mediated HIV-1 transmission and its expression is upregulated by newly synthesized HIV-1 Nef
    Christopher M Coleman
    Center for Retrovirus Research, Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA
    Retrovirology 8:26. 2011
    ..However, the role of type I IFN and tetherin in HIV-1 infection of DCs and DC-mediated viral transmission remains unknown...
  2. ncbi Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial
    Paul Spearman
    Department of Pediatrics, Pediatric Infectious Diseases, Emory University School of Medicine, 2015 Uppergate Drive, Atlanta, GA 30322, United States
    Vaccine 27:243-9. 2009
    ..This study failed to demonstrate that GM-CSF can substantially improve the overall weak immunogenicity of a multiepitope peptide-based HIV vaccine...
  3. ncbi A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers
    Paul Spearman
    Department of Pediatrics, Emory University and Children s Healthcare of Atlanta, Georgia 30322, USA
    J Infect Dis 203:1165-73. 2011
    ..A key missing element in the development of a successful human immunodeficiency virus (HIV) vaccine is an immunogen that can generate broadly cross-neutralizing antibodies against primary isolates of the virus...
  4. ncbi The tetherin/BST-2 coiled-coil ectodomain mediates plasma membrane microdomain localization and restriction of particle release
    Jason Hammonds
    Emory University Department of Pediatrics, Atlanta, Georgia, USA
    J Virol 86:2259-72. 2012
    ..We propose that focal clustering of tetherin via ectodomain interactions plays a role in restriction of particle release...
  5. ncbi Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein
    Peter F Wright
    Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Infect Dis 189:1221-31. 2004
    ....
  6. ncbi Emerging studies of human HIV-specific antibody repertoires
    Mark D Hicar
    Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Vaccine 28:B18-23. 2010
    ..The rapid isolation of large panels of novel human neutralizing antibodies promises to reveal new insights into the fundamental principles underlying antibody-mediated neutralization of HIV...
  7. ncbi Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV
    Mark D Hicar
    Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232 2905, USA
    J Acquir Immune Defic Syndr 54:223-35. 2010
    ..These data demonstrate that Gag-Env pseudovirions recapitulate CD4 and coreceptor binding pocket antigenic structures and can facilitate identification of B-cell clones that secrete neutralizing antibodies...

Research Grants30

  1. Viral and Cellullar Determinants of HIV-1 Assembly
    Paul W Spearman; Fiscal Year: 2010
    ..Together, these experiments will provide important new insights into the interaction of HIV structural proteins with cellular transport pathways. ..
  2. Viral and Cellular Determinants of HIV-1 Assembly
    Paul Spearman; Fiscal Year: 2005
    ..These experiments will answer fundamental questions relevant to HIV-1 particle assembly and may lead to unique opportunities for therapeutic intervention. ..
  3. Role of VPU in Retroviral Particle Assembly
    Paul Spearman; Fiscal Year: 2007
    ..These studies will define the mechanism by which Vpu enhances HIV particle release and will characterize a novel host cell restriction to HIV replication that is present in human cells. ..
  4. Viral and Cellular Determinants of HIV-1 Assembly
    Paul Spearman; Fiscal Year: 2007
    ..Together, these experiments will provide important new insights into the interaction of HIV structural proteins with cellular transport pathways. ..
  5. Pseudovirion Formation by Live Vector HIV Vaccines
    Paul Spearman; Fiscal Year: 2007
    ..Together, these experiments will provide important insights into the role of pseudovirions in generating HIV-specific immune responses following live vector immunization. ..
  6. Novel Assays for Inhibitors of HIV Assembly
    Paul Spearman; Fiscal Year: 2007
    ..abstract_text> ..
  7. Defining Neutralization Breadth in HIV+ Human Serum
    Paul W Spearman; Fiscal Year: 2010
    ..By understanding in detail the antibody responses present in these HIV-infected individuals, we will gain insights into how we can better design a protective HIV vaccine that can generate similar responses in uninfected persons. ..
  8. Development of Enhanced HIV-1 Pseudovirion Vaccines
    Paul Spearman; Fiscal Year: 2006
    ..abstract_text> ..
  9. Novel FRET-based Assays for HIV Assembly Inhibitors
    Paul Spearman; Fiscal Year: 2004
    ..These assays will be used to screen libraries of compounds available from NIH, Vanderbilt, and industrial partners to identify candidate inhibitors of Gag-Gag interactions. ..
  10. Role of VPU in Retroviral Particle Assembly
    Paul W Spearman; Fiscal Year: 2011
    ..This project could reveal new ways to inhibit this aspect of HIV, resulting in new drugs against HIV and potentially against other harmful viruses. ..